FDA Grants Priority Review for BridgeBio's BBP-418 NDA for LGMD2I/R9 with November PDUFA Date

summarizeSummary

BridgeBio Pharma announced the FDA has accepted its New Drug Application for BBP-418 for LGMD2I/R9 with Priority Review, setting a PDUFA target action date of November 27, 2026.

check_boxKey Events · Product Development and Regulatory · BBIO

• FDA Accepts NDA for BBP-418

  The U.S. Food and Drug Administration (FDA) has accepted BridgeBio's New Drug Application (NDA) for BBP-418 for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

• Granted Priority Review

  The FDA granted Priority Review designation to BBP-418, indicating its potential to offer significant improvements over available therapies for a serious condition.

• PDUFA Target Action Date Set

  A Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026, has been assigned, providing a clear timeline for a potential regulatory decision.

• Potential First-in-Class Therapy

  If approved, BBP-418 would be the first and only therapy for LGMD2I/R9 and the first approved treatment for any form of limb-girdle muscular dystrophy.

auto_awesomeAnalysis · BBIO · Life Sciences

The FDA's acceptance of the New Drug Application (NDA) for BBP-418 with Priority Review is a significant de-risking event for BridgeBio's lead pipeline asset. Priority Review indicates the FDA believes BBP-418 could offer a significant improvement over existing therapies for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a condition with high unmet medical need. The assigned PDUFA date provides a clear timeline for a potential approval and market launch, and the absence of an advisory committee meeting suggests the FDA is comfortable with the submitted data, further increasing the likelihood of approval. If approved, BBP-418 would be the first and only therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD, representing a major commercial opportunity.